AkashiY.J., SpringerJ., LainscakM., AnkerS.D.Review: Atrial natriuretic peptide and related peptides.Clin Chem Lab Med2007 Jul 30; [Epub ahead of print].
2.
RascherW., TulassayT., LangR.E.Atrial natriuretic peptide in plasma of volume-overloaded children with chronic renal failure.Lancet1985; 2: 303–5.
3.
YamamotoY., HigaT., KitamuraK., TanakaK., KangawaK., MatsuoH.Plasma concentration of atrial natriuretic polypeptide in chronic hemodialysis patients.Regul Pept Suppl1985; 4: 110–12.
4.
JaegerJ.Q., MehtaR.L.Assessment of dry weight in dialysis patients: an over view.J Am Soc Nephrol1999; 10: 392–403.
5.
KouwP.M., KoomanJ.P., CheriexE.C., OlthofC.G., de VriesPMJM, LeunissenK.M.L.Assessment of postdialysis dry weight.J Am Soc Nephrol1993; 4: 98–104.
6.
SureshM., FarringtonK.Natriuretic peptides and the dialysis patient.Semin Dial2005; 18: 409–19.
7.
MaiselA.S., KrishnaswamyP., NowakR.M., McCordJ., HollanderJ.E., DucP.Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.N Engl J Med2002; 347: 161–7.
8.
WeberM., HammC.Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine.Heart2006; 92: 843–9.
9.
HallC.Essential biochemistry and physiology of (NT-pro) BNP.Eur J Heart Fail2004; 6: 257–60.
10.
de LemosJ.A., McGuireD.K., DrznerM.H.B-type natriuretic peptide in cardiovascular disease.Lancet2003; 362: 316–22.
11.
RosnerM.H.Measuring risk in end-stage renal disease: is N-terminal pro brain natriuretic peptide a useful marker?Kidney Int2007; 71: 481–3.
12.
KrollM.H., SrisawasdiP.The clearance of BNP modeled using the NT-proBNP-BNP relationship.Biosystems2007; 88: 147–55.
13.
SchouM., DalsgaardM.K., ClemmesenO., DawsonE.A., YoshigaC.C., NielsenH.B.Kidneys extract BNP and NT-proBNP in healthy young men.J Appl Physiol2005; 99: 1676–80.
deFilippiC.R., SeligerS.L., MaynardS., ChristensonR.H.Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality.Clin Chem2007; 53: 1511–19.
16.
VickeryS., PriceC.P., JohnR.I., AbbasN.A., WebbM.C., KempsonM.E.B-type natriuretic peptide (BNP) and aminoterminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy.Am J Kidney Dis2005; 46: 610–20.
17.
MarkP.B., StewartG.A., GansevoortR.T., PetrieC.J., McDonaghT.A., DargieH.J.Diagnostic potential of circulating natriuretic peptides in chronic kidney disease.Nephrol Dial Transplant2006; 21: 402–10.
18.
WangA.Y., LamC.W., YuC.M., WangM., ChanI.H., ZhangY.N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients.J Am Soc Nephrol2007; 18: 321–30.
19.
LeeS.W., SongJ.H., KimG.A., LimH.J., KimM.J.Plasma brain natriuretic peptide concentration on assessment of hydration status in hemodialysis patient.Am J Kidney Dis2003; 41: 1257–66.
20.
WahlH.G., GrafS., RenzH., FassbinderW.Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis.Clin Chem2004; 50: 1071–4.
21.
van de PolA.C., FrenkenL.A., MoretK., BaumgartenR., van der SandeF.M., BeerenhoutC.M.An evaluation of blood volume changes during ultrafiltration pulses and natriuretic peptides in the assessment of dry weight in hemodialysis patients.Hemodial Int2007; 11: 51–61.
22.
MadsenL.H., LadefogedS., CorellP., SchouM., HildebrandtP.R., AtarD.N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis.Kidney Int2007; 71: 548–54.
23.
LuchnerA., HengstenbergC., LowelH., RieggerG.A., SchunkertH., HolmerS.Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP.Hypertension2005; 46: 118–23.
24.
Chenevier-GobeauxC., ClaessensY.E., VoyerS., DesmoulinsD., EkindjianO.G.Influence of renal function on N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients admitted for dyspnoea in the emergency department: comparison with brain natriuretic peptide (BNP).Clin Chim Acta2005; 361: 167–75.
25.
MallamaciF., ZoccaliC., TripepiG., BenedettoF.A., ParlongoS., CataliottiA.Diagnostic potential of cardiac natriuretic peptides in dialysis patients.Kidney Int2001; 59: 1559–66.
26.
deFilippiC.R., FinkJ.C., NassC.M., ChenH., ChristensonR.N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis.Am J Kidney Dis2005; 46: 35–44.
27.
van KimmenadeR.R., JanuzziJ.L.Jr., BaggishA.L., LainchburyJ.G., Bayes-GenisA., RichardsA.M.Amino-terminal pro-brain natriuretic peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction?J Am Coll Cardiol2006; 48: 1621–7.
28.
BavbekN., AkayH., AltayM., UzE., TurgutF., UyarM.E.Serum BNP concentration and left ventricular mass in CAPD and automated peritoneal dialysis patients.Perit Dial Int2007; 27: 663–8.
29.
ZoccaliC., MallamaciF., BenedettoF.A., TripepiG., ParlongoS., CataliottiA.Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients.J Am Soc Nephrol2001; 12: 1508–15.
30.
NaganumaT., SugimuraK., WadaS., YasumotoR., SugimuraT., MasudaC.The prognostic role of brain natriuretic peptides in hemodialysis patients.Am J Nephrol2002; 22: 437–44.
31.
AppleF.S., MurakamiM.M., PearceL.A., HerzogC.A.Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death.Clin Chem2004; 50: 2279–85.
32.
SommererC., BeimlerJ., SchwengerV., HeckeleN., KatusH.A., GiannitsisE.Cardiac biomarkers and survival in haemodialysis patients.Eur J Clin Invest2007; 37: 350–6.
33.
FagugliR.M., PalumboB., RicciardiD., PasiniP., SantirosiP., VecchiL.Association between brain natriuretic pep-tide and extracellular water in hemodialysis patients.Nephron Clin Pract2003; 95: c60–6.
34.
ClericoA., CaprioliR., Del RyS., GiannessiD.Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis.J Endocrinol Invest2001; 24: 24–30.
35.
SheenV., BhallaV., Tulua-TataA., BhallaM.A., WeissD., ChiuA.The use of B-type natriuretic peptide to assess volume status in patients with end-stage renal disease.Am Heart J2007; 153: 244.e1-5.
36.
KoningsC.J., KoomanJ.P., SchonckM., DammersR., CheriexE., Palmans MeulemansA.P.Fluid state, blood pressure, and cardiovascular abnormalities in patients on peritoneal dialysis.Perit Dial Int2002; 22: 477–87.
37.
LeeJ.A., KimD.H., YooS.J., OhD.J., YuS.H., KangE.T.Association between serum N-terminal pro-brain natriuretic pep-tide concentration and left ventricular dysfunction and extracellular water in continuous ambulatory peritoneal dialysis patients.Perit Dial Int2006; 26: 360–5.
38.
BoudvilleN.C., CordyP., MillmanK., FairbairnL., SharmaA., LindsayR.Blood pressure, volume, and sodium control in an automated peritoneal dialysis population.Perit Dial Int2007; 27: 537–43.
